Today, Mizuho Reiterates Buy Rating for Pacira Pharmaceuticals Inc. (PCRX)

Today, Mizuho Reiterates Buy Rating for Pacira Pharmaceuticals Inc. (PCRX)

Pacira Pharmaceuticals Inc. (NASDAQ:PCRX)‘s stock had its “buy” rating reaffirmed by investment analysts at Mizuho in a report issued on Saturday. They presently have a $46.00 price objective on the stock. Mizuho’s target price suggests a potential upside of 40.03% from the stock’s previous close.

PCRX has been the subject of several other reports. BMO Capital Markets upgraded Pacira Pharmaceuticals from an “underperform” rating to a “market perform” rating and reduced their price objective for the stock from $36.00 to $35.00 in a report on Thursday, October 27th. They noted that the move was a valuation call. Cowen and Company assumed coverage on Pacira Pharmaceuticals in a report on Wednesday, September 7th. They issued a “market perform” rating for the company. Zacks Investment Research upgraded Pacira Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $52.00 price objective for the company in a report on Wednesday, August 10th. Piper Jaffray Cos. reiterated an “overweight” rating and issued a $81.00 price objective on shares of Pacira Pharmaceuticals in a report on Wednesday, August 3rd. Finally, Brean Capital reiterated a “hold” rating on shares of Pacira Pharmaceuticals in a report on Friday, August 5th. One analyst has rated the stock with a sell rating, five have assigned a hold rating and seven have assigned a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus price target of $71.18.

Shares of Pacira Pharmaceuticals (NASDAQ:PCRX) opened at 32.85 on Friday. Pacira Pharmaceuticals has a 12 month low of $30.25 and a 12 month high of $80.25. The stock’s 50 day moving average price is $34.21 and its 200 day moving average price is $38.86. The company’s market capitalization is $1.23 billion.

Pacira Pharmaceuticals (NASDAQ:PCRX) last issued its quarterly earnings results on Wednesday, November 2nd. The company reported $0.20 earnings per share for the quarter, beating the consensus estimate of ($0.02) by $0.22. Pacira Pharmaceuticals had a negative return on equity of 1.52% and a negative net margin of 13.37%. The firm earned $68.40 million during the quarter, compared to the consensus estimate of $67.16 million. During the same period last year, the company earned $0.32 earnings per share. The company’s revenue was up 10.0% on a year-over-year basis. On average, analysts forecast that Pacira Pharmaceuticals will post $0.55 EPS for the current year.

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. BNP Paribas Arbitrage SA boosted its position in Pacira Pharmaceuticals by 111.3% in the third quarter. BNP Paribas Arbitrage SA now owns 3,051 shares of the company’s stock worth $104,000 after buying an additional 1,607 shares during the last quarter. BlackRock Inc. boosted its position in Pacira Pharmaceuticals by 60.5% in the second quarter. BlackRock Inc. now owns 4,007 shares of the company’s stock worth $135,000 after buying an additional 1,510 shares during the last quarter. Acrospire Investment Management LLC boosted its position in Pacira Pharmaceuticals by 2,000.0% in the third quarter. Acrospire Investment Management LLC now owns 4,200 shares of the company’s stock worth $144,000 after buying an additional 4,000 shares during the last quarter. US Bancorp DE boosted its position in Pacira Pharmaceuticals by 8.5% in the second quarter. US Bancorp DE now owns 5,010 shares of the company’s stock worth $169,000 after buying an additional 394 shares during the last quarter. Finally, Teacher Retirement System of Texas boosted its position in Pacira Pharmaceuticals by 13.6% in the second quarter. Teacher Retirement System of Texas now owns 5,184 shares of the company’s stock worth $175,000 after buying an additional 622 shares during the last quarter.

Pacira Pharmaceuticals Company Profile

Related posts

Leave a Comment